Daily Stock Analysis, CLCD, CoLucid Pharmaceuticals Inc, priceseries

CoLucid Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
46.53
Close
46.53
High
46.53
Low
46.53
Previous Close
46.53
Daily Price Gain
0.00
YTD High
46.65
YTD High Date
Feb 8, 2017
YTD Low
31.25
YTD Low Date
Jan 6, 2017
YTD Price Change
10.33
YTD Gain
28.52%
52 Week High
46.65
52 Week High Date
Feb 8, 2017
52 Week Low
5.26
52 Week Low Date
May 9, 2016
52 Week Price Change
40.13
52 Week Gain
626.95%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 15. 2015
6.39
Sep 22. 2015
6.79
5 Trading Days
6.18%
Link
LONG
May 25. 2016
6.17
Jun 9. 2016
6.75
10 Trading Days
9.35%
Link
LONG
Jun 29. 2016
7.09
Jul 21. 2016
8.92
15 Trading Days
25.85%
Link
LONG
Sep 8. 2016
20.64
Oct 17. 2016
34.84
27 Trading Days
68.81%
Link
LONG
Nov 9. 2016
32.25
Nov 21. 2016
34.58
8 Trading Days
7.23%
Link
Company Information
Stock Symbol
CLCD
Exchange
NasdaqGM
Company URL
http://www.colucid.com
Company Phone
781-365-2596
CEO
Thomas P. Mathers
Headquarters
Massachusetts
Business Address
222 THIRD STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001348649
About

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of mig...

Description

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of migraine headaches in adults. The company is also developing IV lasmiditan, which is in Phase II clinical trial for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.